This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kramer, G. Articles by Linder, S. Search for Related Content PubMed PubMed Citation Articles by Kramer, G. Articles by Linder, S.

Differentiation between Cell Death Modes Using Measurements of Different Soluble Forms of Extracellular Cytokeratin 18

¹ Department of Urology, University of Vienna, Vienna, Austria; ² Cancer Center Karolinska, Department of Oncology and Pathology, Karolinska Institute and Hospital, Stockholm, Sweden; ³ Department of Obstetrics and Gynecology, Maasland Ziekenhuis, Sittard, the Netherlands; and ⁴ Department of Pathology, Atrium Heerlen, Medical Centre, Heerlen, the Netherlands

Cytokeratins are released from carcinoma cells by unclear mechanisms and are commonly used serum tumor markers (TPA, TPS, and CYFRA 21–1). We here report that soluble cytokeratin-18 (CK18) is released from human carcinoma cells during cell death. During necrosis, the cytosolic pool of soluble CK18 was released, whereas apoptosis was associated with significant release of caspase-cleaved CK18 fragments. These results suggested that assessments of different forms of CK18 in patient sera could be used to examine cell death modes. Therefore, CK18 was measured in local venous blood collected during operation of patients with endometrial tumors. In most patient sera, caspase-cleaved fragments constituted a minor fraction of total CK18, suggesting that tumor apoptosis is not the main mechanism for generation of circulating CK18. Monitoring of different CK18 forms in peripheral blood during chemotherapy of prostate cancer patients showed individual differences in the patterns of release. Importantly, several examples were observed where the increase of apoptosis-specific caspase-cleaved CK18 fragments constituted only a minor fraction of the total increase. These results suggest that cell death of epithelially derived tumors can be assessed in patient serum and suggest that tumor apoptosis may not necessarily be the dominating death mode in many tumors in vivo.

This article has been cited by other articles:

				J.-M. Hou, A. Greystoke, L. Lancashire, J. Cummings, T. Ward, R. Board, E. Amir, S. Hughes, M. Krebs, A. Hughes, et al. Evaluation of Circulating Tumor Cells and Serological Cell Death Biomarkers in Small Cell Lung Cancer Patients Undergoing Chemotherapy Am. J. Pathol., August 1, 2009; 175(2): 808 - 816. [Abstract] [Full Text] [PDF]

				E. Hernlund, E. Hjerpe, E. Avall-Lundqvist, and M. Shoshan Ovarian carcinoma cells with low levels of {beta}-F1-ATPase are sensitive to combined platinum and 2-deoxy-D-glucose treatment Mol. Cancer Ther., July 1, 2009; 8(7): 1916 - 1923. [Abstract] [Full Text] [PDF]

				E. Dean, D. Jodrell, K. Connolly, S. Danson, J. Jolivet, J. Durkin, S. Morris, D. Jowle, T. Ward, J. Cummings, et al. Phase I Trial of AEG35156 Administered as a 7-Day and 3-Day Continuous Intravenous Infusion in Patients With Advanced Refractory Cancer J. Clin. Oncol., April 1, 2009; 27(10): 1660 - 1666. [Abstract] [Full Text] [PDF]

				D. Micha, J. Cummings, A. Shoemaker, S. Elmore, K. Foster, M. Greaves, T. Ward, S. Rosenberg, C. Dive, and K. Simpson Circulating Biomarkers of Cell Death After Treatment with the BH-3 Mimetic ABT-737 in a Preclinical Model of Small-Cell Lung Cancer Clin. Cancer Res., November 15, 2008; 14(22): 7304 - 7310. [Abstract] [Full Text] [PDF]

				J. Cummings, C. Hodgkinson, R. Odedra, P. Sini, S. P. Heaton, K. E. Mundt, T. H. Ward, R. W. Wilkinson, J. Growcott, A. Hughes, et al. Preclinical evaluation of M30 and M65 ELISAs as biomarkers of drug induced tumor cell death and antitumor activity Mol. Cancer Ther., March 1, 2008; 7(3): 455 - 463. [Abstract] [Full Text] [PDF]

				M. H. Olofsson, T. Ueno, Y. Pan, R. Xu, F. Cai, H. van der Kuip, T. E. Muerdter, M. Sonnenberg, W. E. Aulitzky, S. Schwarz, et al. Cytokeratin-18 Is a Useful Serum Biomarker for Early Determination of Response of Breast Carcinomas to Chemotherapy Clin. Cancer Res., June 1, 2007; 13(11): 3198 - 3206. [Abstract] [Full Text] [PDF]

				P. Luciani, S. Gelmini, E. Ferrante, A. Lania, S. Benvenuti, S. Baglioni, G. Mantovani, I. Cellai, F. Ammannati, A. Spada, et al. Expression of the Antiapoptotic Gene Seladin-1 and Octreotide-Induced Apoptosis in Growth Hormone-Secreting and Nonfunctioning Pituitary Adenomas J. Clin. Endocrinol. Metab., November 1, 2005; 90(11): 6156 - 6161. [Abstract] [Full Text] [PDF]

				H. Erdal, M. Berndtsson, J. Castro, U. Brunk, M. C. Shoshan, and S. Linder Induction of lysosomal membrane permeabilization by compounds that activate p53-independent apoptosis PNAS, January 4, 2005; 102(1): 192 - 197. [Abstract] [Full Text] [PDF]

				M. B. Omary, P. A. Coulombe, and W.H. I. McLean Intermediate Filament Proteins and Their Associated Diseases N. Engl. J. Med., November 11, 2004; 351(20): 2087 - 2100. [Full Text] [PDF]